Aravive — Investor Presentation (August 2019)
23 slides from Aravive's investor presentation, Aug 12, 2019
Slide 1: Aravive Corporate Presentation August 2019
Aravive Corporate Presentation August 2019 © 2019 Aravive, Inc. Exhibit 99.1
Slide 2: Important Information: Forward-Looking Statements
Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally i
Slide 3: Aravive Offers First and Potentially Best-In-Class Opportunities in Oncology and Fibrosis
Aravive Offers First and Potentially Best-In-Class Opportunities in Oncology and Fibrosis © 2019 Aravive, Inc. Uniquely positioned in competitive landscape Robust pipeline addressing significant drivers of mortality in oncology and fibrosis: metastasis and drug resistance AVB-500: high affinity deco
Slide 4: Robust Development Pipeline in Oncology and Fibrosis
Robust Development Pipeline in Oncology and Fibrosis © 2019 Aravive, Inc. **Phase 1 was conducted in healthy volunteers, allowing any next AVB-500 study to be either a phase 1b or phase 2 study Expansion into additional oncology indications where pre-clinical and biological rationale is strong Indic
Slide 5: GAS6-AXL Role in Cancer: Strong Biology, but Challenging Target with Poor Drugs
GAS6-AXL Role in Cancer: Strong Biology, but Challenging Target with Poor Drugs Identified at Stanford by Aravive’s scientific founder Increased GAS6/AXL expression and signaling seen in many cancers and correlated with a poor prognosis Robust target validation: differentially expressed in cancer, a
Slide 6: AVB-500 Inhibits AXL Signaling by Neutralizing GAS6
AVB-500 Inhibits AXL Signaling by Neutralizing GAS6 Addresses Potency and Selectivity Challenges of Targeting GAS/AXL Pathway Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 Kd for human GAS6 is ~140 femtomolar ~200 fold greater affinity for human GAS6
Slide 7: GAS6/AXL Signaling Drives Activation, Migration and Invasion of Abnormal Cells
GAS6/AXL Signaling Drives Activation, Migration and Invasion of Abnormal Cells Inhibiting GAS6 preclinically Has anti-tumor activity in many tumor types, including ovarian, pancreatic, breast, and kidney Blocks tumor invasion & metastasis Overcomes acquired drug resistance Ameliorates desmoplasia an
Slide 8: AVB-500: Dual Modes Act on Tumor Directly and Tumor Microenvironment
AVB-500: Dual Modes Act on Tumor Directly and Tumor Microenvironment to Address Metastasis © 2019 Aravive, Inc. Source: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology Tumor micro environment drugs include anti-angiogenic agents Avastin and Zaltrap
Slide 9: Decoy Receptor is the Best Approach for Potent and Selective Inhibition of GAS6/AXL Signaling
Decoy Receptor is the Best Approach for Potent and Selective Inhibition of GAS6/AXL Signaling © 2019 Aravive, Inc. WT AXL has pM Affinity; AVB-500 has fM Affinity Selectivity limited by RTK homology Off-target toxicity Multiple resistance mechanisms Many potential competitors Decoy AXL Receptor AXL
Slide 10: Our Molecules Achieve Prolonged Target Engagement with High Potency & Selectivity
© 2019 Aravive, Inc. Our Molecules Achieve Prolonged Target Engagement with High Potency & Selectivity For Improved Activity *Established Metastatic Disease **Methods in Rankin et al 2012 J Clin Invest. 2017;127(1):183–198 Affinity (potency) Matters Selectivity Matters In vivo Activity Matters
Slide 11: Development Program in Platinum-Resistant Ovarian Cancer
Development Program in Platinum-Resistant Ovarian Cancer Initial indication with robust preclinical biological rationale, unmet clinical needs, and feasibility to establish POC © 2019 Aravive, Inc.
Slide 12: Attractive Drug Attributes
Attractive Drug Attributes Biomarker driven clinical development to accelerate program Low toxicity and no anticipated drug-drug interactions facilitate combination studies (unlike small molecules) © 2019 Aravive, Inc. The ability to combine with common standards of care allows access to a large tot
Slide 13: Aravive's Innovative Development Plan Accelerates Time to POC
Aravive’s Innovative Development Plan Accelerates Time to POC Year 1 Year 2 Year 3 Year 4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 *http://www.appliedclinicaltrialsonline.com/why-are-cancer-clinical-trials-increasing-duration Abbreviations: IND= Investigational New Drug application; PD= pharm
Slide 14: AVB-500 Demonstrates Tolerability & Proof-of-Mechanism in Phase 1 Trial
Trial Design Dosed 42 Healthy Volunteers Two-dosing regimens: SAD portion consisting of 4 sequential dose escalation cohorts RD portion consisting of 4 single doses once weekly Primary objective to assess safety and tolerability Secondary objective to assess PK/PD and to establish proof-of-mechanism
Slide 15: Platinum Resistant Ovarian Cancer: Compelling Efficacy Signal in Phase 1b Portion
Platinum Resistant Ovarian Cancer: Compelling Efficacy Signal in Phase 1b Portion of Phase 1b/2 Study Safety lead-in portion of the Phase 1b/2 trial is designed to confirm dose predicted based on Phase 1 study in healthy volunteers Primary objective to assess safety and tolerability; Secondary objec
Slide 16: Response Rates for Standard of Care in Platinum Resistant Ovarian Cancer
Response Rates for Standard of Care in Platinum Resistant Ovarian Cancer are Well-Established at ~11% (10-15%) Primary References: (1) J Clin Oncol. 2007 Jul 1;25(19):2811-8 (2) J Clin Oncol. 2010 Jul 1;28(19):3107-14 (3) J Clin Oncol. 2012 Nov 1;30(31):3841-7 (4) J Clin Oncol. 2013 Dec 10;31(35):44
Slide 17: Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-500: Phase 2 Portion
Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-500: Phase 2 Portion © 2019 Aravive, Inc. Status: FPI expected 4Q19/1Q20, topline interim analysis data expected end of 2020 Randomized (2:1), double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-500 in combination wit
Slide 18: AVB Proteins Offer Franchise with Demonstrated Tolerability and Early Activity in Cancer
AVB Proteins Offer Franchise with Demonstrated Tolerability and Early Activity in Cancer with PD Biomarker for Accelerated Development © 2019 Aravive, Inc.
Slide 19: Robust Development Pipeline in Oncology and Fibrosis
Robust Development Pipeline in Oncology and Fibrosis © 2019 Aravive, Inc. **Phase 1 was conducted in healthy volunteers, allowing any next AVB-500 study to be either a phase 1b or phase 2 study Expansion into additional oncology indications where pre-clinical and biological rationale is strong Indic
Slide 20: Experienced, Methodical, Efficient Development Execution
Experienced, Methodical, Efficient Development Execution Strong Clinical Development Team Dev Plan Enabled Bifurcated Strategy- Oncology and Fibrosis 4Q 2017- IND filed 1Q 2018- FIH in NHV initiated 2Q 2018- POM in NHV 3Q 2018- Tolerability in NHV 4Q 2018- P1b in ovarian cancer initiated 2Q 2019- PO
Slide 21: Well Capitalized to Execute on Clinical Plans
Well Capitalized to Execute on Clinical Plans NASDAQ: ARAV; Shares Outstanding*: 11.3M basic © 2019 Aravive, Inc. * As of Q2 2019 Cash and cash equivalents*: $48.4M Cash and cash equivalents expected to enable the company to fund its operating plans through 2020
Slide 22: Aravive Opportunity Summary
Aravive Opportunity Summary © 2019 Aravive, Inc. Strong biology addressing significant clinical need with competitive positioning Validated pathway drives activation, migration and invasion of abnormal cells AVB-500 PK/PD profile allowed seamless transition from preclinical to clinical studies Propr
Slide 23: Thank You
Thank You © 2019 Aravive, Inc.